GuidelineDer Urologe. Ausg. A2011
[Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations].
Guideline in Der Urologe. Ausg. A, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review.World journal of urology · 2022Pooled it
- [Follow-up in patients with testicular germ cell tumors-an update].Urologie (Heidelberg, Germany) · 2025Review
- [Follow-up of testicular germ cell tumors-historical aspects and current recommendations].Der Urologe. Ausg. A · 2022Review
- Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased?Journal of cancer research and clinical oncology · 2019Article
- [Diagnosis, treatment and follow-up of testicular cancer].Der Urologe. Ausg. A · 2017Review
- Testicular seminoma clinical stage 1: treatment outcome on a routine care level.Journal of cancer research and clinical oncology · 2016Article
- [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].Der Urologe. Ausg. A · 2016Article
- [What is new in 2011 regarding testicular cancer].Der Urologe. Ausg. A · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear treatment recommendations for patients with testicular cancer exist and their stringent application has led to significant improvements in remission and survival rates. Moreover, active surveillance has become a cornerstone in the management of clinical stage I seminomatous and nonseminomatous germ cell tumors. On the other hand, the existing recommendations for the follow-up of testis cancer patients differ widely and have been changed frequently in recent years. MATERIAL AND
methodsFollow-up recommendations in this young patient population have to be as evidence-based as possible, feasible in order to ensure adherence, and should not be harmful. Primarily, attention has to be paid to the negative impact of unnecessary radiation exposure.
resultsRecently, new evidence has become available regarding the relapse pattern of different disease stages of testicular cancer, the use of imaging at follow-up, and the risks of excessive radiation due to imaging, in particular that of CT scans. An interdisciplinary multinational working group consisting of urologists, medical oncologists, and radiation oncologists has reviewed and discussed the current evidence and on this basis formulated new recommendations for patients with germ cell tumors of the testis.
Indexed as
Identifiers
21503662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.